



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



LY2828360

Item No. 26791

CAS Registry No.: 1231220-79-3
Formal Name: 8-(2-chlorophenyl)-2-methyl-6-(4-methyl-1-piperazinyl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine
MF: C₂₂H₂₇ClN₆O
FW: 426.9
Purity: ≥98%
UV/Vis.: λ_{max}: 219, 284 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LY2828360 is supplied as a crystalline solid. A stock solution may be made by dissolving the LY2828360 in the solvent of choice. LY2828360 is soluble in the organic solvent chloroform, which should be purged with an inert gas, at a concentration of approximately 30 mg/ml.

Description

LY2828360 is a cannabinoid (CB) receptor 2 agonist ($K_i = 40.3$ nM).¹ It selectively activates CB₂ over CB₁ in a GTPγS binding assay (EC_{50} s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Item No. 10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days.² It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.

References

- Hollinshead, S.P., Tidwell, M.W., Palmer, J., *et al.* Selective cannabinoid receptor type 2 (CB₂) agonists: Optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. *J. Med. Chem.* **56**(14), 5722-5733 (2013).
- Lin, X., Dhopeswarkar, A.S., Huijbreghse, M., *et al.* Slowly signaling G protein-biased CB₂ cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence. *Mol. Pharmacol.* **93**(2), 49-62 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/11/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM